Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and
safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the
treatment of moderate to severe plaque-type psoriasis. This new medicine will be compared to
a so-called placebo medicine over 12 weeks with a 12 weeks treatment extension possible.